Orthopediatrics Corp (KIDS) Stock Analysis and Metrics

Orthopediatrics

NASDAQ: KIDS

$18.84 ▲ +0.12 (+0.64%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap443.38 Mn

P/E-11.18

P/S1.82

Div. Yield0.00

ROIC (Qtr)-0.07

Total Debt (Qtr)5.24 Mn

Revenue Growth (1y) (Qtr)13.26

Add ratio to table…

About

OrthoPediatrics Corp. is a medical device company that designs develops and markets implants instruments and specialized braces for children with orthopedic conditions. The company is headquartered in Warsaw Indiana and serves pediatric orthopedic surgeons hospitals and medical facilities worldwide. OrthoPediatrics Corp. was founded in 2007 with the goal of addressing the unmet needs of young patients requiring orthopedic care. Over time the company has expanded its product lines to cover trauma deformity correction scoliosis and sports medicine interventions.

Revenue is generated primarily from the sale of orthopedic implants instruments and specialty bracing products. The company also earns income from operating orthotic and prosthetic clinics that provide non surgical bracing and related clinical services. Customers include hospitals ambulatory surgery centers and private medical practices that treat pediatric patients. The firm consigns implant and instrument sets to hospitals to facilitate surgery and drive recurring revenue. International sales are supported by a network of stocking distributors and direct sales representatives in key markets.

The company operates through the following segments.

• This segment includes implants instruments external fixation components specialized braces and bone graft substitutes for the femur tibia pelvis upper and lower extremities. It also provides clinical orthotic and prosthetic services to support postoperative care. Revenue from this segment is driven by sales of trauma plating systems and flexible intramedullary nails.

• This segment offers spinal implants rod systems sub laminar banding devices navigation guides and specialized braces for the treatment of spinal deformities. It also includes orthotic and prosthetic services for scoliosis management. Growth in this area comes from increased adoption of vertebral body tethering systems and scoliosis specific braces.

• This segment covers anterior cruciate ligament reconstruction systems medial patellofemoral ligament products and other sports related implant and bracing solutions. It also includes enabling technologies such as perfusion sensing devices and robotic insertion tools. Demand for sports medicine products is supported by surgeon preference for less invasive ligament reconstruction techniques.

OrthoPediatrics Corp. is recognized as the only global medical device company that concentrates exclusively on the pediatric orthopedic market. This focus differentiates it from larger orthopedic suppliers such as Johnson & Johnson MedTech Medtronic plc Smith & Nephew plc Orthofix and Hanger clinics. The company’s competitive advantages stem from its deep surgeon relationships its comprehensive product portfolio its scalable sales model and its unique culture of continuous improvement. These strengths enable OrthoPediatrics Corp. to maintain a leading position as a category specialist and to create barriers to entry for competitors. The firm also invests heavily in clinical education and surgeon training which reinforces brand loyalty and supports long term growth. The company continues to invest in research and development to launch new implant platforms and bracing solutions each year. These efforts aim to expand the addressable market and strengthen relationships with pediatric orthopedic surgeons worldwide.

The company serves hospitals ambulatory surgery centers and pediatric orthopedic clinics that treat children with musculoskeletal conditions. Its customer base includes major health systems community hospitals and independent surgical centers across the United States and in more than seventy five international markets. While specific customer names are not disclosed the company’s revenue is driven by repeat orders from high volume pediatric centers and clinic networks. The firm also supplies products to military medical centers and charitable clinics that provide care in underserved regions. Long term partnerships with group purchasing organizations help secure consistent order volumes and pricing stability.

Investment Thesis

▲ Bull case

OrthoPediatrics Corp. is positioned at the forefront of a multiyear innovation super cycle driven by clinically differentiated products such as 3P Hip, Vertiglyde, Traxio, and Veraxis, which collectively address significant unmet needs in pediatric orthopedics and are expected to drive higher average selling prices, improved gross margins, and stronger returns on invested capital. These products are generating early demand signals despite limited set availability, with strong surgeon adoption—evidenced by nearly 80 trained Vertiglyde surgeons and multiple hospital requests for Traxio quotes—indicating pent-up demand that will translate into meaningful revenue impact as set deployments increase in the second half of 2026 and beyond. The capital efficiency of these new platforms, requiring less deployed capital per dollar of revenue generated compared to legacy systems, enhances profitability and free cash flow conversion, supporting the company’s guidance for adjusted EBITDA of approximately $25 million and free cash flow breakeven in 2026. Furthermore, the company’s international expansion, particularly in EMEA following full EU MDR approval for its T&D, scoliosis, and external fixation portfolios, is unlocking previously constrained markets, with early traction in agency-driven sales and Brazil’s structural improvements through distributor acquisition stabilizing cash flow and normalizing ordering patterns, setting the stage for accelerated growth in LATAM as a potential tailwind in coming quarters.
OrthoPediatrics Corp.’s OPSB segment continues to outperform with over 20% year-over-year growth in Q1 2026, driven by new product introductions like the modular hip brace and Traxio Halo Gravity Traction System, clinic expansion via greenfield openings and acqui-hires, and same-store sales strength, positioning the business to exceed its goal of 27 territories by 2027. This growth is reinforced by strategic bundling opportunities across its three-pillar OPSB strategy—sales force expansion, targeted product innovation, and disciplined clinic growth—which enhances customer retention and increases lifetime value per account. The early success of Traxio, which addresses a critical gap in early onset scoliosis care by providing an FDA-approved alternative to in-hospital fabrication, creates a powerful halo effect that drives adoption of complementary products such as Response, Vertiglyde, and future Ellie and Veraxis systems, thereby increasing cross-sell potential and strengthening the company’s value proposition to children’s hospitals. With Ellie and Veraxis targeting first-in-patient procedures by year-end and representing a sub-$100 million market opportunity with minimal competition, the company is well-positioned to capture significant share in a niche where it holds a first-mover advantage through pediatric-specific design, unlike adult-adapted competitors.
OrthoPediatrics Corp. is building a defensible, integrated pediatric orthopedics platform that leverages synergies across its Trauma and Deformity, Scoliosis, and OPSB businesses, as evidenced by increasing pull-through from EOS products like Vertiglyde into legacy fusion systems such as Response, and the planned integration of Traxio with the Orthex external fixation platform to enhance cross-selling between surgical and nonsurgical offerings. This ecosystem approach strengthens customer lock-in and supports broader contract opportunities with pediatric hospitals seeking comprehensive, single-vendor solutions for complex spinal deformity care. The company’s deliberate investments in artificial intelligence—including AI agents for Playbook workflow management, presurgical planning, and OPSB clinic efficiency—are transitioning from experimentation to scaled implementation in 2026, with a corporate objective to deploy six to eight targeted AI agents that promise tangible operational and clinical benefits, further improving margins and differentiating the company from peers still reliant on manual processes. Combined with a strengthened balance sheet via the $20 million delayed-draw term loan from Braidwell LP—which provides interest-only, discretionary capital through 2029 without dilution—OrthoPediatrics Corp. has the financial flexibility to fund growth initiatives opportunistically while maintaining disciplined capital deployment, reducing reliance on equity markets and preserving shareholder value during its innovation-driven expansion phase.

OrthoPediatrics Corp. is positioned at the forefront of a multiyear innovation super cycle driven by clinically differentiated products such as 3P Hip, Vertiglyde, Traxio, and Veraxis, which collectively address significant unmet needs in pediatric orthopedics and are expected to drive higher average selling prices, improved gross margins, and stronger returns on invested capital. These products are generating early demand signals despite limited set availability, with strong surgeon adoption—evidenced by nearly 80 trained Vertiglyde surgeons and multiple hospital requests for Traxio quotes—indicating pent-up demand that will translate into meaningful revenue impact as set deployments increase in the second half of 2026 and beyond. The capital efficiency of these new platforms, requiring less deployed capital per dollar of revenue generated compared to legacy systems, enhances profitability and free cash flow conversion, supporting the company’s guidance for adjusted EBITDA of approximately $25 million and free cash flow breakeven in 2026. Furthermore, the company’s international expansion, particularly in EMEA following full EU MDR approval for its T&D, scoliosis, and external fixation portfolios, is unlocking previously constrained markets, with early traction in agency-driven sales and Brazil’s structural improvements through distributor acquisition stabilizing cash flow and normalizing ordering patterns, setting the stage for accelerated growth in LATAM as a potential tailwind in coming quarters.
OrthoPediatrics Corp.’s OPSB segment continues to outperform with over 20% year-over-year growth in Q1 2026, driven by new product introductions like the modular hip brace and Traxio Halo Gravity Traction System, clinic expansion via greenfield openings and acqui-hires, and same-store sales strength, positioning the business to exceed its goal of 27 territories by 2027. This growth is reinforced by strategic bundling opportunities across its three-pillar OPSB strategy—sales force expansion, targeted product innovation, and disciplined clinic growth—which enhances customer retention and increases lifetime value per account. The early success of Traxio, which addresses a critical gap in early onset scoliosis care by providing an FDA-approved alternative to in-hospital fabrication, creates a powerful halo effect that drives adoption of complementary products such as Response, Vertiglyde, and future Ellie and Veraxis systems, thereby increasing cross-sell potential and strengthening the company’s value proposition to children’s hospitals. With Ellie and Veraxis targeting first-in-patient procedures by year-end and representing a sub-$100 million market opportunity with minimal competition, the company is well-positioned to capture significant share in a niche where it holds a first-mover advantage through pediatric-specific design, unlike adult-adapted competitors.
OrthoPediatrics Corp. is building a defensible, integrated pediatric orthopedics platform that leverages synergies across its Trauma and Deformity, Scoliosis, and OPSB businesses, as evidenced by increasing pull-through from EOS products like Vertiglyde into legacy fusion systems such as Response, and the planned integration of Traxio with the Orthex external fixation platform to enhance cross-selling between surgical and nonsurgical offerings. This ecosystem approach strengthens customer lock-in and supports broader contract opportunities with pediatric hospitals seeking comprehensive, single-vendor solutions for complex spinal deformity care. The company’s deliberate investments in artificial intelligence—including AI agents for Playbook workflow management, presurgical planning, and OPSB clinic efficiency—are transitioning from experimentation to scaled implementation in 2026, with a corporate objective to deploy six to eight targeted AI agents that promise tangible operational and clinical benefits, further improving margins and differentiating the company from peers still reliant on manual processes. Combined with a strengthened balance sheet via the $20 million delayed-draw term loan from Braidwell LP—which provides interest-only, discretionary capital through 2029 without dilution—OrthoPediatrics Corp. has the financial flexibility to fund growth initiatives opportunistically while maintaining disciplined capital deployment, reducing reliance on equity markets and preserving shareholder value during its innovation-driven expansion phase.

▼ Bear case

OrthoPediatrics Corp.’s reliance on weather-sensitive clinic operations in its OPSB segment introduces operational volatility that management downplayed during the Q&A, as evidenced by their acknowledgment that January and February clinic shutdowns due to weather impacted first-quarter performance, with only partial recovery in March and some spillover into Q2, suggesting that external environmental factors could continue to disrupt consistent same-store sales growth and clinic expansion timelines, particularly in regions prone to seasonal extremes, thereby undermining the predictability of OPSB’s over 20% growth trajectory and increasing execution risk beyond what is reflected in current guidance.
Despite strong early demand signals for products like 3P Hip and Vertiglyde, OrthoPediatrics Corp. remains constrained by limited set availability and a deliberate, conservative rollout strategy that prioritizes surgeon access and feedback over rapid revenue capture, as highlighted by management’s admission that they are intentionally withholding sets from the loaner pool to broaden user access, which delays meaningful top-line contribution and prolongs the time to scale, with David Bailey explicitly stating that even established products like PMP Tibia—now two and a half years on market—are still being rolled out and impacting growth, implying that the full revenue potential of the current super cycle may not materialize until 2027 or 2028, leaving near-term guidance dependent on legacy product performance rather than the promised innovation tailwind.
OrthoPediatrics Corp.’s international growth, while strong at 22% in Q1 2026, is heavily reliant on legacy product replenishment through agency markets in EMEA and faces normalization risks in LATAM despite the Brazilian distributor acquisition, as Fred Hite noted that most international revenue currently stems from replenishment orders rather than new product adoption, and EU MDR approval, while enabling market access, does not guarantee accelerated uptake—especially given the company’s own caution about not getting ahead of itself on set deployment timing—raising concerns that international expansion may plateau once legacy product demand stabilizes, without sufficient new product conversion to sustain double-digit growth, particularly if surgeon training and hospital adoption curves for complex systems like Veraxis and Ellie prove slower than anticipated due to reimbursement hurdles or institutional procurement cycles.
OrthoPediatrics Corp.’s path to free cash flow breakeven in 2026 remains contingent on sustained operating leverage from G&A expense control, yet the company acknowledged that G&A dollars may rise modestly in Q2 and Q3 due to clinic expansion and recent acquisitions, with Fred Hite noting that leverage will come “very nicely” but offering no quantifiable assurance that expense growth will remain below revenue growth, creating downside risk if OPSB clinic rollouts or international integration efforts incur higher-than-expected costs, particularly as the company pursues greenfield and acqui-hire strategies without detailing specific capital expenditure expectations, potentially pressuring margins and delaying profitability targets if scale does not deliver the anticipated leverage.

OrthoPediatrics Corp.’s reliance on weather-sensitive clinic operations in its OPSB segment introduces operational volatility that management downplayed during the Q&A, as evidenced by their acknowledgment that January and February clinic shutdowns due to weather impacted first-quarter performance, with only partial recovery in March and some spillover into Q2, suggesting that external environmental factors could continue to disrupt consistent same-store sales growth and clinic expansion timelines, particularly in regions prone to seasonal extremes, thereby undermining the predictability of OPSB’s over 20% growth trajectory and increasing execution risk beyond what is reflected in current guidance.
Despite strong early demand signals for products like 3P Hip and Vertiglyde, OrthoPediatrics Corp. remains constrained by limited set availability and a deliberate, conservative rollout strategy that prioritizes surgeon access and feedback over rapid revenue capture, as highlighted by management’s admission that they are intentionally withholding sets from the loaner pool to broaden user access, which delays meaningful top-line contribution and prolongs the time to scale, with David Bailey explicitly stating that even established products like PMP Tibia—now two and a half years on market—are still being rolled out and impacting growth, implying that the full revenue potential of the current super cycle may not materialize until 2027 or 2028, leaving near-term guidance dependent on legacy product performance rather than the promised innovation tailwind.
OrthoPediatrics Corp.’s international growth, while strong at 22% in Q1 2026, is heavily reliant on legacy product replenishment through agency markets in EMEA and faces normalization risks in LATAM despite the Brazilian distributor acquisition, as Fred Hite noted that most international revenue currently stems from replenishment orders rather than new product adoption, and EU MDR approval, while enabling market access, does not guarantee accelerated uptake—especially given the company’s own caution about not getting ahead of itself on set deployment timing—raising concerns that international expansion may plateau once legacy product demand stabilizes, without sufficient new product conversion to sustain double-digit growth, particularly if surgeon training and hospital adoption curves for complex systems like Veraxis and Ellie prove slower than anticipated due to reimbursement hurdles or institutional procurement cycles.
OrthoPediatrics Corp.’s path to free cash flow breakeven in 2026 remains contingent on sustained operating leverage from G&A expense control, yet the company acknowledged that G&A dollars may rise modestly in Q2 and Q3 due to clinic expansion and recent acquisitions, with Fred Hite noting that leverage will come “very nicely” but offering no quantifiable assurance that expense growth will remain below revenue growth, creating downside risk if OPSB clinic rollouts or international integration efforts incur higher-than-expected costs, particularly as the company pursues greenfield and acqui-hire strategies without detailing specific capital expenditure expectations, potentially pressuring margins and delaying profitability targets if scale does not deliver the anticipated leverage.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password